Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | EVP, Corp Strategy & Develop | August 10, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,041 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Gift · Disposed 257 · Balance 31,041 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,520 | $251.18 | $884,144.10 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · nonDerivative · entry 7 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,356 F3 · price: This transaction was executed in multiple trades at prices ranging from $250.91 to $251.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 580 | $250.23 | $145,132.82 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · nonDerivative · entry 6 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,876 F2 · price: This transaction was executed in multiple trades at prices ranging from $250.04 to $250.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,639 | $249.09 | $657,350.36 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · nonDerivative · entry 5 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,456 F1 · price: This transaction was executed in multiple trades at prices ranging from $248.83 to $249.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,042 | $144.67 | $440,086.14 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,205 | $109.34 | $350,434.70 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 492 | $88.05 | $43,320.60 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2020 Filed Nov 5, 2020 16:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 285 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028214 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,356 Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 6,685 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001127602-20-018380 · form4.xml · derivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,685 Underlying: Common Stock · 6,685 shares Expires 2030-05-29 F2 · shares: Stock Options vest as follows: 1,671 on May 29, 2021, 1,671 on May 29, 2022, 1,671 on May 29, 2023 and 1,672 on May 29, 2024. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:06 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018380 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,641 F1 · shares: Unvested restricted stock units vest in one-fourth increments on May 29, 2021, 2022, 2023 and 2024. Read SEC document |
| May 18, 2020 Filed May 19, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 350 | $174.65 | $61,127.89 |
DisclosureSEC source: 0001127602-20-017158 · form4.xml · nonDerivative · entry 5 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,637 F3 · price: This transaction was executed in multiple trades at prices ranging from $174.62 to $174.6858. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $88.05 | $0.00 |
DisclosureSEC source: 0001127602-20-017158 · form4.xml · derivative · entry 7 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,000 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,350 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-20-017158 · form4.xml · derivative · entry 6 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,350 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,899 | $168.81 | $827,002.15 |
DisclosureSEC source: 0001127602-20-017158 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,987 F2 · price: This transaction was executed in multiple trades at prices ranging from $168.605 to $169.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 10,519 | $168.00 | $1,767,167.81 |
DisclosureSEC source: 0001127602-20-017158 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 F1 · price: This transaction was executed in multiple trades at prices ranging from $167.54 to $168.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,000 | $88.05 | $264,150.00 |
DisclosureSEC source: 0001127602-20-017158 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,350 | $73.70 | $246,895.00 |
DisclosureSEC source: 0001127602-20-017158 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 26, 2020 17:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 303 | $162.46 | $49,225.38 |
DisclosureSEC source: 0001127602-20-007863 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,055 Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 17:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 322 | $173.64 | $55,912.08 |
DisclosureSEC source: 0001127602-20-007124 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,358 Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 17:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 315 | $173.64 | $54,696.60 |
DisclosureSEC source: 0001127602-20-007124 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,680 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 17:31 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 317 | $173.64 | $55,043.88 |
DisclosureSEC source: 0001127602-20-007124 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,995 Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 3,846 | $159.07 | $611,783.22 |
DisclosureSEC source: 0001127602-20-004580 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,312 Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 20:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 10,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004580 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,158 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on February 24, 2017. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $138.17 | $27,634.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 30 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,079 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 179 | $138.16 | $24,730.64 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 29 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,279 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 507 | $138.15 | $70,042.05 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 28 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,458 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $138.14 | $27,628.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 27 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,965 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 137 | $138.10 | $18,919.70 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 26 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,165 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 70 | $138.10 | $9,666.65 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 25 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,302 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 600 | $138.08 | $82,848.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 24 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $138.07 | $41,421.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 23 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,972 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 240 | $138.06 | $33,134.40 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 22 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,272 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 60 | $138.06 | $8,283.30 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 21 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,512 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 108 | $138.05 | $14,909.40 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 20 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,572 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $138.04 | $13,804.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 19 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,680 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $138.03 | $41,409.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 18 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,780 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 30 | $138.03 | $4,140.75 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 17 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,080 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $138.02 | $41,406.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 16 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,110 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 5 | $138.02 | $690.08 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 15 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,410 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 11 | $138.01 | $1,518.11 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 14 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,415 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $138.00 | $13,800.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 13 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,426 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 230 | $137.99 | $31,737.70 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 12 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,526 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.98 | $13,798.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 11 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,756 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 195 | $137.97 | $26,904.15 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 10 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,856 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $137.92 | $27,584.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 9 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,051 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 299 | $137.91 | $41,235.09 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 8 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,251 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $137.90 | $41,370.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 7 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,550 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.89 | $13,789.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 6 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,850 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $137.88 | $13,788.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 5 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,950 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $137.87 | $41,361.00 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,050 Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 11:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 99 | $137.86 | $13,648.14 |
DisclosureSEC source: 0001127602-19-010921 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,350 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.